Wear Lingo or Libre Rio. Add the AI.
Abbott's OTC sensors brought CGM to retail. SNAQ adds the AI nutritionist layer the Lingo and Libre Rio apps don't offer, with a peer-reviewed RCT behind it.
In short.
Abbott's OTC sensors, Lingo (wellness) and Libre Rio (T2D non-insulin), bring FreeStyle Libre's CGM technology to consumers with a coaching layer in the companion app. SNAQ is the AI nutritionist that pairs with both: photo carb counting validated at 5.5 g mean absolute error, glucose prediction before you eat, and a published RCT. Wear the Abbott sensor; use SNAQ for RCT-backed meal intelligence on top.
At a glance.
- Lingo is positioned for wellness; Libre Rio is positioned for T2D not on insulin. Both ride the FreeStyle Libre platform (6M+ users globally).
- SNAQ adds photo carb counting (validated at 5.5 g mean absolute error) and predictive glucose response.
- SNAQ integrates with both Abbott sensors and 18+ other devices, so a future sensor switch isn't a problem.
- SNAQ has a peer-reviewed RCT (+6.6 pp Time-in-Range, eClinicalMedicine 2025).
- Lingo and Libre Rio companion apps are single-vendor; SNAQ is a neutral hub.
Feature by feature.
Structured comparison based on publicly available information, last reviewed May 2026.
| Feature | SNAQ | Abbott Lingo / Libre Rio |
|---|---|---|
| What it is | AI nutritionist with predictive glucose model | 14-day OTC sensors (Lingo wellness, Libre Rio T2D non-insulin) |
| Photo meal logging accuracy | ✅ Validated at 5.5 g mean absolute carb error | ⚠ In-app coaching, accuracy not peer-reviewed |
| Glucose prediction before the meal | ✅ | ❌ Not in the Lingo or Libre Rio companion apps |
| AI coaching | ✅ Proactive | ⚠ Lingo Count, recommendations |
| Cross-data pattern insights | ✅ Across meals, glucose, insulin, activity and weight; weekly progression and simple summaries | ⚠ Lingo Count + daily/weekly snapshots, glucose-centric |
| Peer-reviewed clinical evidence (product-specific) | ✅ RCT, eClinicalMedicine 2025 | ✅ Libre platform broadly validated |
| Multi-device support | ✅ 20+ devices (FreeStyle Libre, Dexcom, Eversense and more) | ⚠ Abbott-only, no Dexcom or third-party hub |
| Sensor-optional use | ✅ Works fully without a CGM or BGM; supports intermittent sensor wear | ❌ Companion apps require the Lingo or Libre Rio sensor |
| Provider dashboard | ✅ SNAQ Care for clinicians, includes meal, glucose, activity, insulin data and more, 500+ clinicians | ❌ Not in the Lingo or Libre Rio companion apps (LibreView serves prescribed Libre only) |
| Best for | Anyone who wants RCT-backed AI nutrition guidance | Wellness users (Lingo) and T2D non-insulin users (Libre Rio) starting with a retail CGM |
Sources: Herzig D. et al., JMIR mHealth and uHealth, 2020 (carb counting accuracy) Piazza et al., eClinicalMedicine 2025 (RCT NCT05671679, Time-in-Range) SNAQ research overview Lingo by Abbott product pages Abbott Launches Lingo & Libre Rio in U.S. Biowearables Market, Abbott Newsroom
Why users switch.
Add the AI nutrition layer
The Lingo app provides general recommendations. SNAQ adds photo carb counting and personalised glucose-response prediction on the same sensor data.
One hub for now and later
If you start with Lingo and later move to Libre 3 or a different sensor, SNAQ keeps your data continuous. Abbott's apps don't read Dexcom data.
Cover T1D and GLP-1 too
Lingo and Libre Rio are positioned outside T1D. If you need T1D, AID or GLP-1 support, SNAQ covers all three.
Honest take.
Choose SNAQ if…
- You want predictive, AI-driven nutrition guidance on top of an Abbott sensor.
- You want device flexibility for the future.
- You're a T1D, AID or GLP-1 user.
Consider Abbott Lingo / Libre Rio if…
- You only want the Abbott companion app's wellness coaching and don't need predictive meal guidance.
- You don't want to install a second app.
Bottom line
Lingo and Libre Rio are excellent entry points to CGM. SNAQ is the AI nutrition layer that makes the most of either sensor, and works with the rest of the device ecosystem too.
Published randomised controlled trial evidence, measured against standard care in T1D patients on automated insulin delivery systems.
Source: eClinicalMedicine (The Lancet), 2025 · Piazza et al. · NCT05671679